Saad Z. Usmani, MD, MBA, FACP, discusses how the CEPHEUS study, presented at ASH 2024, along with its expanded analysis of minimal residual disease (MRD) outcomes, provides valuable insights into ...
discusses how the definition of the transplant-ineligible population for multiple myeloma is evolving while also addressing the challenges of standardizing minimal residual disease (MRD ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback